Chai Discovery

Chai Discovery announced a collaboration with Roche to use Chai's AI models and platform in a number of drug discovery programs across Roche's therapeutic areas. Chai builds computer-aided design tools for protein-based therapeutics, and its latest model, Chai-3, is described by the company as achieving high target success rates and binding affinities, including against challenging targets. The deal is the latest in a series of 2026 collaborations Chai has announced with leading pharmaceutical companies; the announcement gives no program counts, specific targets or timelines.

Chai Discovery announced a collaboration with Roche to use Chai's AI models and platform in a number of drug discovery programs across Roche's therapeutic areas. Chai builds computer-aided design tools for protein-based therapeutics, and its latest model, Chai-3, is described by the company as achieving high target success rates and binding affinities, including against challenging targets. The deal is the latest in a series of 2026 collaborations Chai has announced with leading pharmaceutical companies; the announcement gives no program counts, specific targets or timelines.